Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Generic & Biosimilar Medicines Programme: 2023 Company Profiles

The Generic & Biosimilar Medicines Programme’s 2023 Company Profiles publication assesses five market-leading companies, examining their current efforts to make quality-assured essential medicines available and affordable in low- and middle-income countries (LMICs).

Date

26 September 2023

Read the full report

The generics industry plays a critical role in widening access to medicine globally, primarily by manufacturing off-patent medicines at high volumes and supplying them at lower costs than the original patented medicines. Yet, despite this potential, generic and biosimilar medicines remain out of reach for many in LMICs.  

A new assessment by the Access to Medicine Foundation, carried out using the Foundation’s first-of-its-kind Analytical Framework, profiles five of the world’s leading producers of generic and biosimilar medicines  – Cipla, Hikma, Sun Pharma, Teva, and Viatris - and identifies what steps they are currently taking on key access-to-medicine priorities.  

What's in the 2023 report?

5 COMPANY PROFILES

Each profile assesses each company's respective performance against its own potential in terms of capabilities, portfolios, and scopes, and showcases its initiatives and strategies aimed at enhancing access to its products in LMICs. The profiles are divided into three research areas: Expanding Access, Supply & Quality, and Research & Development. Tailored opportunities for the companies to increase access are included within the Company Profiles. 

4 KEY FINDINGS

The report includes four key findings that draw on data from across the companies. This analysis reveals insights related to product registration, affordability and access strategies, supply and local availability, and adaptive R&D. Each key finding also identifies where companies can focus their attention as they step up efforts to expand access to their essential medicines.  

For the very first time, we're shining a spotlight on the actions, efforts, and commitments of leading generic and biosimilar medicine manufacturers to broaden access to lifesaving medicines in LMICs. Although there are standout examples of action, clear opportunities also exist for companies to ramp up their efforts and to work closely with local implementers, governments, and global health organisations to continue to break down barriers for the millions who either lack adequate access or are forced to go without the medicines they need.

Claudia Martínez

Research Programme Manager, Access to Medicine Foundation

What’s next?  

Given their portfolios and footprints, these five companies can have a huge impact on access in LMICs. They can now work to significantly enhance their efforts by acting on the opportunities and the tailored recommendations set out in their respective company profiles. The findings in the report also demonstrate where other companies may be able to learn from their peers and adopt similar positive actions, where relevant, to further improve access and ensure their products reach the people who need them most – no matter where they live. 

Claudia Martínez

Director of Research

cmartinez@accesstomedicinefoundation.org

Get in touch

Resource centre

Read the key findings from our report on generic medicines manufacturers
Key findings

Companies have a collectively broad regulatory reach in LMICs, yet many essential products are not widely registered

26 September 2023
Key findings

Companies are using access strategies to expand access to their products in LMICs, yet efforts fall short for the poorest patients

26 September 2023
Key findings

Despite initiatives to strengthen manufacturing, further efforts needed to safeguard product availability

26 September 2023

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved